Anlu Chen
Senior Scientist, Computational Oncology Abbvie
Anlu Chen is a Senior Scientist in Computational Oncology at AbbVie, where she leads bioinformatics analyses across the drug development pipeline from target exploration to Phase 2 clinical trials. Her expertise spans preclinical model selection, including cell lines, PDX, and CDX models, with a focus on ensuring these models accurately represent patient populations. Anlu has pioneered novel drug target prioritization using Generative AI approaches and developed machine learning methods to enhance precision oncology treatment forecasting. She has presented her research on model selection and patient representation at ASHG and AACR conferences.
Seminars
Wednesday 28th January 2026
Mapping Preclinical Model Transcriptomes to Patient Tumor Profiles to Improve Translational Predictability
9:00 am
- Comparing isogenic, PDX, and other oncology models against TCGA patient transcriptomes to identify which preclinical systems accurately represent tumor biology and subsequently predict drug efficacy in clinical trials
- Highlighting gaps in fibroblast, stromal, and immune-related gene expression to understand limitations of standard models for translational oncology research
- Applying transcriptomic-guided model prioritization to reduce the number of screened models while ensuring broad coverage of clinically relevant patient profiles
